Markets and Economy

Read our latest market commentary on of-the-moment trends so you can make informed investment decisions

Stocks Up Ahead of Inflation Data, Oracle Earnings

After Friday's weak jobs report raised rate cut odds, investors face two key inflation reports that could help decide how steep the Fed's cuts might be. Oracle reports tomorrow.

Looking to the Futures

Crude oil futures (/CLV25) fell for the third consecutive day on Friday as oil traders covered long position ahead of an OPEC+ meeting this past weekend.

Weekly Trader's Outlook

Markets limped into the weekend after Friday's early morning sell-off reversed what had all been a new all-time high print in the S&P 500.

Lower Bond Yields: You Can't Get There From Here

The Federal Reserve may cut rates a couple of times by year-end, but the pace and magnitude of easing in 2026 is unclear. There are still some roadblocks to lower bond yields.

Take the Long Way Home: Is Housing Bottoming?

The housing market remains out of sync with the broader economy as affordability is depressed, but an improvement in supply and demand dynamics might be on the horizon.

Sector Views: Monthly Stock Sector Outlook

Our outlook on the 11 S&P 500 equity sectors.

How to Effectively Read Federal Reserve Minutes

Learning to read the Fed minutes effectively can help traders understand the central bank's policy-making process, sentiment, and rate expectations, all of which can impact markets.

Will a Weak Dollar Enhance International Returns?

International stocks have outperformed the broad U.S. stock market so far this year. If the U.S. dollar continues to weaken, it could boost international returns even more.

Nvidia Earnings Ahead with China, AI Spend in Focus

Nvidia, the biggest AI-chip firm, reports Wednesday. Watchlist items include the pathway toward resuming H20 chip sales in China, revenue guidance, and Blackwell growth.

Health Care Sector Struggles as Pharma Tariffs Loom

U.S. health care stocks are having their worst year relative to the S&P 500 in years, and the next blow could be pharma tariffs. Still, some retail investors see opportunity.